71 related articles for article (PubMed ID: 29052111)
1. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
[TBL] [Abstract][Full Text] [Related]
2. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
De Mattos-Arruda L; Bidard FC; Won HH; Cortes J; Ng CK; Peg V; Nuciforo P; Jungbluth AA; Weigelt B; Berger MF; Seoane J; Reis-Filho JS
Mol Oncol; 2014 Feb; 8(1):150-8. PubMed ID: 24220311
[TBL] [Abstract][Full Text] [Related]
3. Genetic analysis of PALB2 gene WD40 domain in canine mammary tumour patients.
Çıldır ÖŞ; Özmen Ö; Kul S; Rişvanlı A; Özalp G; Sabuncu A; Kul O
Vet Med Sci; 2024 May; 10(3):e1366. PubMed ID: 38527110
[TBL] [Abstract][Full Text] [Related]
4. Discovery of mutations in homologous recombination genes in African-American women with breast cancer.
Ding YC; Adamson AW; Steele L; Bailis AM; John EM; Tomlinson G; Neuhausen SL
Fam Cancer; 2018 Apr; 17(2):187-195. PubMed ID: 28864920
[TBL] [Abstract][Full Text] [Related]
5. Bayesian meta-analysis of penetrance for cancer risk.
Ruberu TLM; Braun D; Parmigiani G; Biswas S
Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819308
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Detection of a Novel Germline
De Angelis C; Nardelli C; Concolino P; Pagliuca M; Setaro M; De Paolis E; De Placido P; Forestieri V; Scaglione GL; Ranieri A; Lombardo B; Pastore L; De Placido S; Capoluongo E
Front Oncol; 2021; 11():602523. PubMed ID: 33718150
[TBL] [Abstract][Full Text] [Related]
7. Correlational study on mitochondrial DNA mutations as potential risk factors in breast cancer.
Li L; Chen L; Li J; Zhang W; Liao Y; Chen J; Sun Z
Oncotarget; 2016 May; 7(21):31270-83. PubMed ID: 27121313
[TBL] [Abstract][Full Text] [Related]
8. Risk-reducing surgery in
Masanam MK; Pitcher CW; Sogunro O; Starks LK; Murray AB; Boisvert ME
Transl Breast Cancer Res; 2022; 3():37. PubMed ID: 38751533
[TBL] [Abstract][Full Text] [Related]
9. PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Pharoah PDP; Song H; Dicks E; Intermaggio MP; Harrington P; Baynes C; Alsop K; ; Bogdanova N; Cicek MS; Cunningham JM; Fridley BL; Gentry-Maharaj A; Hillemanns P; Lele S; Lester J; McGuire V; Moysich KB; Poblete S; Sieh W; Sucheston-Campbell L; Widschwendter M; ; Whittemore AS; Dörk T; Menon U; Odunsi K; Goode EL; Karlan BY; Bowtell DD; Gayther SA; Ramus SJ
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26823519
[TBL] [Abstract][Full Text] [Related]
10. Clinico-genomic findings, molecular docking, and mutational spectrum in an understudied population with breast cancer patients from KP, Pakistan.
Ahmad H; Ali A; Khalil AT; Ali R; Khan I; Khan MM; Ahmed I; Basharat Z; Alorini M; Mehmood A
Front Genet; 2024; 15():1383284. PubMed ID: 38784039
[TBL] [Abstract][Full Text] [Related]
11. Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway.
Padella A; Fontana MC; Marconi G; Fonzi E; Petracci E; Ferrari A; Baldazzi C; Papayannidis C; Ghelli Luserna Di Rorá A; Testoni N; Castellani G; Haferlach T; Martinelli G; Simonetti G
Blood Cancer J; 2021 Jan; 11(1):7. PubMed ID: 33414401
[No Abstract] [Full Text] [Related]
12. Characterizing
Ban IO; Chabert A; Guignard T; Puechberty J; Cabello-Aguilar S; Pujol P; Vendrell JA; Solassol J
Front Oncol; 2024; 14():1355715. PubMed ID: 38487723
[TBL] [Abstract][Full Text] [Related]
13. Genetic Testing for Breast Cancer in the Era of Multigene Panels: Can We Make an Impact on Population Health?
Ginsburg O; Brennan P
J Clin Oncol; 2018 Oct; 36(28):2817-2819. PubMed ID: 30130156
[No Abstract] [Full Text] [Related]
14. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
[TBL] [Abstract][Full Text] [Related]
15. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2.
Boonen RACM; Rodrigue A; Stoepker C; Wiegant WW; Vroling B; Sharma M; Rother MB; Celosse N; Vreeswijk MPG; Couch F; Simard J; Devilee P; Masson JY; van Attikum H
Nat Commun; 2019 Nov; 10(1):5296. PubMed ID: 31757951
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of 84 PALB2 variants of uncertain significance.
Wiltshire T; Ducy M; Foo TK; Hu C; Lee KY; Belur Nagaraj A; Rodrigue A; Gomes TT; Simard J; Monteiro ANA; Xia B; Carvalho MA; Masson JY; Couch FJ
Genet Med; 2020 Mar; 22(3):622-632. PubMed ID: 31636395
[TBL] [Abstract][Full Text] [Related]
19. A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
Rodrigue A; Margaillan G; Torres Gomes T; Coulombe Y; Montalban G; da Costa E Silva Carvalho S; Milano L; Ducy M; De-Gregoriis G; Dellaire G; Araújo da Silva W; Monteiro AN; Carvalho MA; Simard J; Masson JY
Nucleic Acids Res; 2019 Nov; 47(20):10662-10677. PubMed ID: 31586400
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
